検査室確認RSV感染症の急性心イベント;高齢者ワクチン
RSウィルス感染症に関しては診断の確実性が問題と思う
Woodruff, Rebecca C., Michael Melgar, Huong Pham, Laurence S. Sperling, Fleetwood Loustalot, Pam Daily Kirley, Elizabeth Austin, ほか. 「Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection」. JAMA Internal Medicine, 2024年4月15日. https://doi.org/10.1001/jamainternmed.2024.0212 .
一般の臨床の場では、RSVの検査が確立していないため、実感が乏しいというのが現実ではないか?
”GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial”という圧倒的効果が示されているが・・・
population studyなどでインパクトを示して欲しいが、薬価が高いので難しいか!
RSVは冬場のイメージがあるが、温暖国ではそうではないようだ
以下の記事だと、血清学的診断過半数のためなかなか実態が判然としない
以下、Perplexityに質問:"Please list data that suggests the health impact of RSV on older adults."
引用文献:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262134 /
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568930 /
[3] https://www.cambridge.org/core/journals/epidemiology-and-infection/article/burden-of-respiratory-syncytial-virus-in-adults-a-systematic-review-and-metaanalysis/B21A7EE945E90D98BC59C4BFB104E0E7
[4] https://err.ersjournals.com/content/31/166/220105
[5] https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789446
tell me about the efficacy and effectiveness of RS virus vaccination
ChatGPT
ChatGPT
Respiratory Syncytial Virus (RSV) vaccines have shown promising efficacy and safety in recent studies, targeting both older adults and pregnant women to protect newborns.
For older adults, the RSV vaccines Arexvy and another unnamed vaccine have demonstrated significant protective effects. Arexvy has been shown to provide an 83% protection rate against RSV-confirmed lower respiratory tract diseases (LRTD) for at least six months, with common side effects being mild like headache and muscle pain (European Medicines Agency).
Another study reported an efficacy rate of 82.6% in preventing severe RSV disease and a similar overall efficacy for LRTD in individuals over 60 years old (Home | GSK ). This efficacy extends across two RSV seasons, maintaining a strong protection profile without additional benefit from revaccination within this timeframe (Home | GSK ).
For pregnant women, the Pfizer RSVpreF vaccine aims to prevent severe RSV-associated lower respiratory tract illness in newborns through maternal immunization. This vaccine showed an efficacy rate of 81.8% against severe RSV conditions in infants up to 90 days old, with continued effectiveness through the first six months. The vaccine's safety profile has been favorable, though it was noted that a slightly higher incidence of preterm births occurred in the vaccine group compared to placebo (Pfizer).
These findings highlight the potential of RSV vaccines to significantly reduce the burden of this virus among the most vulnerable populations, including older adults and infants. Further research and ongoing clinical trials continue to refine these vaccines' efficacy and safety profiles, supporting their use in broader public health strategies to combat RSV.
この記事が気に入ったらサポートをしてみませんか?